# Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

> **NCT04746131** · PHASE1 · SUSPENDED · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 90 (estimated)

## Conditions studied

- B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** IMM0306

## Key facts

- **NCT ID:** NCT04746131
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-01-15
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 90 (ESTIMATED)
- **Why stopped:** Due to the product development strategy change, without any safety concerns, we (the sponsor of the trial) have decided to request to place the IND (#151570) on inactive status.
- **Last updated:** 2022-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04746131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04746131, "Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04746131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*